Literature DB >> 2223426

Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

H H Zhou1, L B Anthony, A J Wood, G R Wilkinson.   

Abstract

Studies were performed in 13 healthy subjects to determine whether treatment with rifampicin results in induction of the metabolism of mephenytoin. Daily dosing with 600 mg rifampicin for 22 days caused a three to eightfold increase in the 0-8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug to extensive metabolizers of the anticonvulsant. This was accompanied by a 40 to 180% increase in the 0-8 h urinary excretion of the 4'-hydroxy metabolite. Four weeks after discontinuing rifampicin, both metabolic indices had returned to their baseline values. By contrast, rifampicin had no effect on either measures of metabolism in subjects of the poor metabolizer phenotype. Thus, it appears that the activity of the enzyme (P-450 MP) mediating the genetically determined 4'-hydroxylation of S-mephenytoin can be significantly modulated by enzyme inducing agents such as rifampicin and possibly environmental agents with a similar ability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223426      PMCID: PMC1368151          DOI: 10.1111/j.1365-2125.1990.tb03799.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

Review 2.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

Authors:  M Eichelbaum; A S Gross
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Enzyme induction and beta-adrenergic receptor blocking drugs.

Authors:  R A Branch; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

5.  Stereoselective metabolism of mephenytoin in man.

Authors:  A Küpfer; R K Roberts; S Schenker; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

Review 6.  Rifampin drug interactions.

Authors:  A M Baciewicz; T H Self
Journal:  Arch Intern Med       Date:  1984-08

7.  Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat.

Authors:  R James; A Küpfer; J P Villeneuve; R A Branch
Journal:  Drug Metab Dispos       Date:  1981 May-Jun       Impact factor: 3.922

8.  Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.

Authors:  E Jacqz; S D Hall; R A Branch; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

9.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  22 in total

1.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population.

Authors:  B S Doshi; R D Kulkarni; B L Chauhan; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 2.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 5.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

6.  The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.

Authors:  Satoshi Yamada; Hideo Shiohira; Norio Yasui-Furukori; Tomonori Tateishi; Yumiko Akamine; Tsukasa Uno
Journal:  Eur J Clin Pharmacol       Date:  2013-02-24       Impact factor: 2.953

7.  Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.

Authors:  Ritu Rana; Yuping Chen; Stephen S Ferguson; Grace E Kissling; Sailesh Surapureddi; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2010-01-19       Impact factor: 3.922

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.